Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. A, 1997, Pages 87-92

  Barry, Arthur L ^a   Fuchs, Peter C ^a   Brown, Steven D ^a  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN; QUINUPRISTIN; STREPTOGRAMIN DERIVATIVE;

AGAR GEL DIFFUSION; ANTIBIOTIC SENSITIVITY; ARTICLE; ENTEROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 0030928413     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_1.87     Document Type: Article

References (16)

1. Barrière, J. C., Bouanchaud, D. H., Desnottes, J.-F. & Paris, J. M. (1994). Streptogramin analogues. Expert Opinion in Investigational Drugs 3, 115-31.
2. Pass, R. J. (1991). In vitro activity of RP 59500, a semisynthetic injectable pristlnamycin, against staphylococci, streptococci, and enterococci. Antimicrobial Agents and Chemotherapy 35, 553-9.
3. Leclercq, R., Nantas, L., Soussy, C.-J. & Duval, J. (1992). Activity of RP 59500, a new parenteral semisynthetic Streptogramin, against staphylococci with various mechanisms of resistance to macrotide-lincosamide-streptogramin antibiotics. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 67-75.
4. Verbist, L. & Verhaegen, J. (1992). Comparative in-vitro activity of RP 59500. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 39-44.
5. Cremieux, A.-C. & Carbon, C. (1992). Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis. Antimicrobial Agents and Chemotherapy 36, 2069-74.
6. National Committee for Clinical Laboratory Standards. (1992). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A2. NCCLS, Villanova, PA.
7. Crawford, L. & Russell, C. (1986). Comparative adhesion of seven species of streptococci isolated from the blood of patients with sub-acute bacterial endocarditis to fibrin-platelet clots in vitro. Journal of Applied Bacteriology 60, 127-33.
8. Perlman, B. B. & Freedman, L. R. (1971). Experimental endocarditis II: Staphylococcal infection of the aortic valve following placement of polyethylene catheter in the left side of the heart. Yale Journal of Biological Medicine 44, 206-13.
9. Edberg, S. C. (1985). The measurement of antibiotics in human body fluids: techniques and significance. In Antibiotics in Laboratory Medicine, 2nd edn (Lorian, V., Ed.), pp. 381-476. Williams & Wilkins, Baltimore, MD.
10. Flandrois, J.-P., Fardel, G. & Garret, C. (1988). Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 32, 454-7.
11. Daschner, F. D., Franck, U., Kummel, A., Schmidt-Eisenlohr, E., Schlosser, V., Spillner, H. et al. (1987). Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open heart surgery. Journal of Antimicrobial Chemotherapy 19, 359-62.
12. Chambers, H. F. (1992). Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methiciliin-resistant Staphylococcus aureus, Journal of Antimicrobial Chemotherapy 30, Suppl. A, 117-22.
13. Fantin, B., Leclercq, R., Ottiviani, M., Vallois, J.-M., Duval, J., Pocidalo, J.-J. et al. (1994). In vitro activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrobial Agents and Chemotherapy 38, 432-7.
14. Turcotte, A. & Bergeron, M. G. (1992). Pharmacodynamic interaction between RP 59500 and Gram-positive bacteria infecting fibrin clots. Antimicrobial Agents and Chemotherapy 36, 2211-5.
15. Entenza, J. M., Drugeon, H., Glauser, M. P. & Moreillon, P. (1995). Treatment of experimental endocarditis due to erythromycin- susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrobial Agents and Chemotherapy 39, 1419-24.
16. Desnottes, J.-F. & Diallo, N. (1993). RP 59500: In vitro antistaphylococcal bactericidal activity across platelet-fibrin matrices compared to that of vancomycin. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1993. Abstract 763. American Society for Microbiology, Washington, DC.